The ASCO presentation is a non-catalyst event, mechanistic data without new efficacy endpoints or regulatory milestones. Monitor for future registrational trial updates or partnership announcements, which are the primary value drivers for ONCY. The stock has historically shown high volatility on news, but this release lacks material clinical or financial content.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $0.8100entry
- T+1 · 6mo ago 0.00%α −0.59% · $0.8100
- T+5 · 6mo ago +30.86%α +29.19% · $1.06
- T+20 · 5mo ago +14.81%α +16.23% · $0.9300
- T+60 · 3mo ago +4.30%α +1.11% · $0.8448
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showing pelareorep expands pre-existing tumor-reactive immune cells and activates anti-tumor responses in KRAS-mutant pancreatic cancer and early-stage breast cancer. The data are mechanistic and non-clinical, with no new efficacy results or regulatory milestones disclosed.
Key Facts
- Translational data from GOBLET (pancreatic cancer) and AWARE-1 (breast cancer) to be presented at ASCO 2026 (May 29-June 2).
- Data show pelareorep induces antiviral immune response, expands virus-specific T cells, and activates tumor-specific T cells.
- In pancreatic cancer, expansion of pre-existing TIL clones in blood correlated with reductions in tumor volume.
- T-cell receptor sequencing confirmed expansion of mutant KRAS-specific T-cell clones.
- In breast cancer biopsies, gene expression profiling showed increased antiviral/immune gene expression and CXCL13 induction linked to tertiary lymphoid structure formation.
- No new clinical efficacy data (response rates, survival) or regulatory updates were disclosed.
- Pelareorep has Fast Track designation from FDA for colorectal and pancreatic cancer.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $94M market cap.
Risk Factors
- Pelareorep remains investigational with no approved products; clinical trial failure risk is high.
- Company is pre-revenue and dependent on capital markets for funding; dilution risk exists.
- Translational data may not translate to clinical efficacy in registrational trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300127 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers